Evidence map›Paper›PMID 31680842›Full record

ReviewFrontiers in neuroscience2019

Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases.

Maddalena Grieco, Alessandra Giorgi, Maria Cristina Gentile, Maria d'Erme, Susanna Morano, Bruno Maras, Tiziana Filardi

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in neuroscience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07092605 (Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures), which is not on this map. Cited by 110 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
110citing papers in PubMed, 8 pooled it
15.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07092605 early_phase1enrolling by invitationnot on this mapstarted 2024, after this paper: background citation

Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures: For Use in Healthy Individuals Ages 18-65 Who Seek to Improve Their Health and Longevity Through Low-dose (Microdosed) GLP1 Receptor Agonists

TypeinterventionalSponsorAgelessRxRan2024 to 2025Enrolled150ConditionsLongevity, Quality of Life, Mood, InflammationArmsGLP-1, Placebo
3 · Its place in the literature

Who cites it

110 citing papers in PubMed, 8 syntheses or guidelines pooled it, 201 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. GLP-1a: Going beyond Traditional Use.International journal of molecular sciences · 2022
    Pooled it
  7. Pooled it
  8. Antidiabetic Agents for Treatment of Parkinson's Disease: A Meta-Analysis.International journal of environmental research and public health · 2020
    Pooled it
  9. Trial
  10. Trial
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

50 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Maddalena GriecoDepartment of Biochemical Sciences, Faculty of Pharmacy and Medicine, Sapienza University of Rome, Rome, Italy.
Alessandra GiorgiDepartment of Biochemical Sciences, Faculty of Pharmacy and Medicine, Sapienza University of Rome, Rome, Italy.
Maria Cristina GentileDepartment of Experimental Medicine, Faculty of Medicine and Dentistry, Sapienza University of Rome, Rome, Italy.
Maria d'ErmeDepartment of Biochemical Sciences, Faculty of Pharmacy and Medicine, Sapienza University of Rome, Rome, Italy.
Susanna MoranoDepartment of Experimental Medicine, Faculty of Medicine and Dentistry, Sapienza University of Rome, Rome, Italy.
Bruno MarasDepartment of Biochemical Sciences, Faculty of Pharmacy and Medicine, Sapienza University of Rome, Rome, Italy.
Tiziana FilardiDepartment of Experimental Medicine, Faculty of Medicine and Dentistry, Sapienza University of Rome, Rome, Italy.
Sapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes mellitus is one of the major risk factors for cognitive dysfunction. The pathogenesis of brain impairment caused by chronic hyperglycemia is complex and includes mitochondrial dysfunction, neuroinflammation, neurotransmitters' alteration, and vascular disease, which lead to cognitive impairment, neurodegeneration, loss of synaptic plasticity, brain aging, and dementia. Glucagon-like peptide-1 (GLP-1), a gut released hormone, is attracting attention as a possible link between metabolic and brain impairment. Several studies have shown the influence of GPL-1 on neuronal functions such as thermogenesis, blood pressure control, neurogenesis, neurodegeneration, retinal repair, and energy homeostasis. Moreover, modulation of GLP-1 activity can influence amyloid β peptide aggregation in Alzheimer's disease (AD) and dopamine (DA) levels in Parkinson's disease (PD). GLP-1 receptor agonists (GLP-1RAs) showed beneficial actions on brain ischemia in animal models, such as the reduction of cerebral infarct area and the improvement of neurological deficit, acting mainly through inhibition of oxidative stress, inflammation, and apoptosis. They might also exert a beneficial effect on the cognitive impairment induced by diabetes or obesity improving learning and memory by modulating synaptic plasticity. Moreover, GLP-1RAs reduced hippocampal neurodegeneration. Besides this, there are growing evidences on neuroprotective effects of these agonists in animal models of neurodegenerative diseases, regardless of diabetes. In PD animal models, GPL-1RAs were able to protect motor activity and dopaminergic neurons whereas in AD models, they seemed to improve nearly all neuropathological features and cognitive functions. Although further clinical studies of GPL-1RAs in humans are needed, they seem to be a promising therapy for diabetes-associated cognitive decline.

Indexed as

Alzheimer’s diseaseGLP-1 receptor agonistsglucagon-like peptide-1neurodegenerative diseasesParkinson’s diseasetype 2 diabetes

Identifiers

PMID31680842
PMCPMC6813233
OpenAlexW2980881483

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.